FSD Pharma (NASDAQ:HUGE) Stock Rating Reaffirmed by Singular Research

FSD Pharma (NASDAQ:HUGE)‘s stock had its “buy-venture” rating reiterated by equities researchers at Singular Research in a report released on Tuesday, Zacks.com reports. Singular Research also issued estimates for FSD Pharma’s Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.12) EPS.

FSD Pharma Price Performance

Shares of FSD Pharma stock opened at $0.35 on Tuesday. FSD Pharma has a one year low of $0.34 and a one year high of $1.68. The business’s 50 day simple moving average is $0.63 and its two-hundred day simple moving average is $0.86. The stock has a market capitalization of $13.97 million, a P/E ratio of -0.74 and a beta of 0.71.

FSD Pharma (NASDAQ:HUGE) last posted its earnings results on Thursday, March 28th. The company reported ($0.04) earnings per share for the quarter.

Hedge Funds Weigh In On FSD Pharma

A hedge fund recently raised its stake in FSD Pharma stock. AdvisorShares Investments LLC boosted its stake in FSD Pharma Inc. (NASDAQ:HUGE) by 14.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 270,316 shares of the company’s stock after buying an additional 34,679 shares during the period. AdvisorShares Investments LLC owned 0.69% of FSD Pharma worth $249,000 at the end of the most recent reporting period. 1.24% of the stock is currently owned by institutional investors and hedge funds.

FSD Pharma Company Profile

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.